Milan, Italy – April 2, 2019 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with
Milan, Italy, March 5, 2019 – Newron Pharmaceuticals S.p.A. (“Newron”), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the
Sponsoring international study to examine the burden of Rett syndrome on patients and caregivers, featured at Findacure’s Drug Repurposing for Rare Diseases Conference in the UK
Milan, Italy and Morristown, NJ, USA - February 20, 2019 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel
Top line results expected in Q4 2019
Almost all patients continued treatment with sarizotan in a long-term extension study
Positive study results may lead to the approval of the
January 31, 2019 – Milan, Italy and Morristown, NJ – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel
Milan, Italy – January 16, 2019 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with
FURTHER REGULATORY SUBMISSIONS ONGOING WITH AUTHORITIES WORLDWIDE
Milan, Italy – November 30, 2018 – Zambon S.p.A., an international pharmaceutical company strongly committed
- Leading clinicians presented new evidence on treatment options for patients suffering from Rett syndrome and treatment resistant schizophrenia
- Company provided update on its
Luxembourg and Milan – October 30, 2018 – The European Investment Bank (EIB) and Newron Pharmaceuticals S.p.A. (“Newron") (SIX: NWRN), a biopharmaceutical company focused on the
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.